XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.37

-8.4%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (10021)	5/17/1999 10:12:00 AM
From: Edward Paule	Read Replies (2) of 17367

>>> Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties. <<< The conclusions from this study have me confused. >>> Bacteremia was significantly reduced in the rBPI21 group at 2 hours after the start of the E. coli infusion, whereas circulating LPS was less affected. <<< I assume the measurement was of non-bound free-floating LPS. If rBPI21 had only antibacterial properties and no antiendotoxin properties, I would have expected a dramatic increase in circulating LPS after the "potent" killing of the bacteria. I would then expect the higher LPS levels to produce a negligible difference in survivability. But these events didn't happen. I would conclude that the baboons survived because rBPI21 prevented the increase of active circulating LPS that should have occurred following the death of so many gram-negative bacteria. am I What here? missing - Ed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next